|
業務類別
|
Drug Manufacturers - General |
|
業務概覽
|
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographicalperspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines). |
| 公司地址
| 126 East Lincoln Avenue, Rahway, NJ, USA, 07065 |
| 電話號碼
| +1 908 740-4000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.merck.com |
| 員工數量
| 75000 |
| Mr. Richard R. DeLuca, Jr |
Executive Vice President and President, Merck Animal Health |
-- |
24/02/2026 |
| Mr. Robert M. Davis |
Chairman of the Board, President and Chief Executive Officer |
美元 1.65M |
08/04/2026 |
| Mr. Chirfi Guindo |
Senior Vice President, Human Health and Chief Marketing Officer |
-- |
24/02/2026 |
| Mr. Brian Foard |
Executive Vice President and President Specialty, Pharma & Infectious Diseases |
-- |
24/02/2026 |
| Ms. Jennifer Zachary |
Executive Vice President and General Counsel |
美元 1.06M |
24/02/2026 |
| Ms. Caroline A. Litchfield |
Executive Vice President and Chief Financial Officer |
美元 1.17M |
24/02/2026 |
| Mr. Dean Y. Li, M.D.,PhD |
Executive Vice President and President, Merck Research Laboratories |
美元 1.46M |
08/04/2026 |
| Mr. David Michael Williams |
Executive Vice President and Chief Information and Digital Officer |
-- |
24/02/2026 |
| Mr. David R. Maraldo |
Executive Vice President and President, Merck Manufacturing Division |
-- |
24/02/2026 |
| Ms. Betty D. Larson |
Executive Vice President and Chief Human Resources Officer |
-- |
24/02/2026 |
| Mr. Dalton E. Smart, III |
Senior Vice President, Finance, Global Controller and Principal Accounting Officer |
-- |
24/02/2026 |
| Mr. Jannie Oosthuizen |
Senior Vice President and President, Merck U.S. Human Health |
-- |
24/02/2026 |
|
|
| Mr. Douglas M. Baker, Jr |
Independent Director |
08/04/2026 |
| Mr. Inge G. Thulin |
Independent Director |
08/04/2026 |
| Ms. Patricia F. Russo |
Independent Director |
08/04/2026 |
| Mr. Robert M. Davis |
Chairman of the Board, President and Chief Executive Officer |
08/04/2026 |
| Mr. Thomas Henry Glocer |
Lead Independent Director |
08/04/2026 |
| Ms. Pamela J. Craig |
Independent Director |
08/04/2026 |
| Dr. Risa J. Lavizzo-Mourey,M.D. |
Independent Director |
08/04/2026 |
| Ms. Kathy J. Warden |
Independent Director |
08/04/2026 |
| Dr. Paul B. Rothman, M.D. |
Independent Director |
08/04/2026 |
| Mr. Surendralal L. Karsanbhai |
Independent Director |
08/04/2026 |
| Ms. Mary Ellen Coe |
Independent Director |
08/04/2026 |
| Dr. Christine E. Seidman, M.D. |
Independent Director |
08/04/2026 |
| Dr. Stephen L. Mayo, PhD |
Independent Director |
08/04/2026 |
|
|
|
|
